PTC Therapeutics Inc
NASDAQ:PTCT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.15
52.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
PTC Therapeutics Inc
Wall Street
Price Targets
PTCT Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
PTCT
is 47.07 USD
with a low forecast of 26.26 USD and a high forecast of 71.4 USD.
PTCT Last Price Targets
PTC Therapeutics Inc
The latest public price target was made on Oct 11, 2024 by
Jeffrey Hung
from
Morgan Stanley
,
who expects
PTCT
stock to
drop by 3%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jeffrey Hung
Morgan Stanley
|
45
USD
Downside 3% |
2 months ago
Oct 11, 2024
|
PTC Therapeutics price target raised to $45 from $32 at Morgan Stanley
TheFly
|
Colin Bristow
UBS
|
47
USD
Upside 2% |
3 months ago
Aug 26, 2024
|
UBS Upgrades PTC Therapeutics (PTCT) to Buy
StreetInsider
|
|
Jeffrey Hung
Morgan Stanley
|
32
USD
Downside 31% |
5 months ago
Jul 12, 2024
|
PTC Therapeutics price target raised to $32 from $30 at Morgan Stanley
TheFly
|
Paul Choi
Goldman Sachs
|
32
USD
Downside 31% |
7 months ago
May 20, 2024
|
PTC Therapeutics (PTCT) PT Raised to $32 at Goldman Sachs, Reiterates Sell
StreetInsider
|
Kelly Shi
Jefferies
|
46
USD
Downside 1% |
7 months ago
May 20, 2024
|
PTC Therapeutics (PTCT) PT Raised to $46 at Jefferies
StreetInsider
|
|
Jeffrey Hung
Morgan Stanley
|
30
USD
Downside 35% |
7 months ago
Apr 26, 2024
|
Morgan Stanley Upgrades PTC Therapeutics (PTCT) to Equalweight
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PTCT's stock price target?
Price Target
47.07
USD
According to Wall Street analysts, the average 1-year price target for
PTCT
is 47.07 USD
with a low forecast of 26.26 USD and a high forecast of 71.4 USD.
What is PTC Therapeutics Inc's Revenue forecast?
Projected CAGR
2%
For the last 8 years the
compound annual growth rate for
PTC Therapeutics Inc's revenue is
50%.
The projected
CAGR
for the next 4 years is
2%.
You don't have any saved screeners yet
